Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $14.1667.

Several analysts recently issued reports on FULC shares. Royal Bank Of Canada increased their price objective on Fulcrum Therapeutics from $5.00 to $7.00 and gave the stock a “sector perform” rating in a report on Thursday, October 30th. HC Wainwright raised their price target on Fulcrum Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Truist Financial set a $14.00 price objective on Fulcrum Therapeutics in a report on Monday, November 24th. Finally, Leerink Partners set a $20.00 price objective on shares of Fulcrum Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, October 21st.

Fulcrum Therapeutics Stock Performance

Shares of FULC opened at $10.74 on Friday. The company has a market capitalization of $580.98 million, a PE ratio of -9.10 and a beta of 3.02. The company’s 50 day moving average price is $9.26 and its 200 day moving average price is $7.78. Fulcrum Therapeutics has a 52 week low of $2.32 and a 52 week high of $12.19.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). On average, equities analysts forecast that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Fulcrum Therapeutics

In related news, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total value of $165,450.00. Following the completion of the sale, the director owned 484,864 shares of the company’s stock, valued at approximately $5,348,049.92. The trade was a 3.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several hedge funds have recently bought and sold shares of FULC. Jump Financial LLC acquired a new stake in shares of Fulcrum Therapeutics in the first quarter worth about $30,000. Brooklyn Investment Group raised its stake in shares of Fulcrum Therapeutics by 209.7% in the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock valued at $35,000 after acquiring an additional 8,254 shares in the last quarter. Quarry LP bought a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at approximately $35,000. Virtu Financial LLC acquired a new stake in Fulcrum Therapeutics in the 1st quarter worth approximately $39,000. Finally, Russell Investments Group Ltd. boosted its position in Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares during the period. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.